FDA notifications. UCB Pharma and FDA issue advisory letter.
D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D004345:Drug Industry; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D000077287:Levetiracetam; D061466:Lopinavir; D010889:Piracetam / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D000927:Anticonvulsants; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D000077287:Levetiracetam; D010889:Piracetam